- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Boston Scientific to buy Target
Acquisition-minded Boston Scientific plans to add another companyto its portfolio. The Natick, MA, catheter developer last monthannounced an agreement to acquire Target Therapeutics, a Fremont,CA, company that develops catheters and other devices used
Acquisition-minded Boston Scientific plans to add another companyto its portfolio. The Natick, MA, catheter developer last monthannounced an agreement to acquire Target Therapeutics, a Fremont,CA, company that develops catheters and other devices used inminimally invasive procedures to treat neurovascular diseases.Target also has a strong position in interventional neuroradiology.
Boston Scientific plans to trade 1.07 shares of its stock foreach Target share in a stock swap valued at $1.1 billion. Targetlast week posted revenues for its third quarter of fiscal 1997(end-December) of $23.9 million, compared with $19 million inthe same period of fiscal 1996. The company had third-quarternet income of $3.8 million, compared with $3.6 million in thesame period a year ago. The acquisition is expected to close inthe second quarter.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
New Research Examines Socioeconomic Factors with Mammography No-Shows
April 10th 2024Patients with Medicaid or means-tested insurance were over 27 percent more likely to miss mammography appointments, and only 65 percent of women with three of more adverse social determinants of health had a mammography exam in a two-year period covering 2020 and 2021, according to new research and a report from the CDC.
